SAN DIEGO, CA — Pfizer has announced it will soon expand its footprint into a 230,000 square-foot life science campus in San Diego to conduct cancer research.

Pfizer Oncology announced last week it has signed a 15-year lease with Breakthrough Properties, a leading global life sciences real estate developer to move into a 10-acre Torrey View property northeast of La Jolla.

Breakthrough Properties is currently putting the finishing touches on the 520,000 square-foot research and development campus, a news release from the developer states. With the agreement with Pfizer, the entire property is now pre-leased.

The New York-based company with a major manufacturing presence in Kalamazoo and Portage will utilize two state-of-the-art research and development buildings for cancer treatment research.

“Breakthrough is proud to support the Pfizer Oncology team as they continue to discover and develop next generation therapies,” said Breakthrough Properties CEO Dan Belldegrun. “Torrey View is an ideal campus for innovation, offering high quality lab infrastructure, as well as unparalleled amenities, expansive open space, and a community of like-minded innovators ranging from established pharmas to growing biotechs.”

Pfizer Oncology will be joined at the campus by leading global medical technology company BD (Becton, Dickinson and Co.), which began a phased move-in of its San Diego workforce in late 2023.

Breakthrough also announced a new collaboration between its StudioLabs platform and Pfizer Ignite, an end-to-end research and development service that connects innovative companies to Pfizer’s suite of research, development and manufacturing services alongside input from an expert advisory network.
Read more at MLIVE